Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib versus imatinib in adults with Philadelphia chromosome-positive chronic-phase CML with suboptimal cytogenetic response to first-line imatinib
NL-OMON31183Phase 3Active, not recruiting
- Sponsor
- Medisch Spectrum Twente
- Start
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic myelogenous leukemia (CML) comparing Imatinib with Nilotinib (2 arms). Primary endpoint: Complete cytogenetic response rate at 12 months. Started Dec 2007; status: active, not recruiting.
02
Drugs
nilotinibimatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON31183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31183.